Table of Content

1 Report Overview
1.1 Pulmonary Embolism Drug Definition
1.2 Market by Type
1.2.1 Global Pulmonary Embolism Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 DS-9231
1.2.3 DS-1040
1.2.4 TRX-1
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Pulmonary Embolism Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pulmonary Embolism Drug Sales
2.1 Global Pulmonary Embolism Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Pulmonary Embolism Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Pulmonary Embolism Drug Revenue by Region
2.3.1 Global Pulmonary Embolism Drug Revenue by Region (2018-2024)
2.3.2 Global Pulmonary Embolism Drug Revenue by Region (2024-2034)
2.4 Global Pulmonary Embolism Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pulmonary Embolism Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Pulmonary Embolism Drug Sales Quantity by Region
2.6.1 Global Pulmonary Embolism Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Pulmonary Embolism Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pulmonary Embolism Drug Sales Quantity by Manufacturers
3.1.1 Global Pulmonary Embolism Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Pulmonary Embolism Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Pulmonary Embolism Drug Sales in 2022
3.2 Global Pulmonary Embolism Drug Revenue by Manufacturers
3.2.1 Global Pulmonary Embolism Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Pulmonary Embolism Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pulmonary Embolism Drug Revenue in 2022
3.3 Global Pulmonary Embolism Drug Sales Price by Manufacturers
3.4 Global Key Players of Pulmonary Embolism Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pulmonary Embolism Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pulmonary Embolism Drug, Product Offered and Application
3.8 Global Key Manufacturers of Pulmonary Embolism Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pulmonary Embolism Drug Sales Quantity by Type
4.1.1 Global Pulmonary Embolism Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Pulmonary Embolism Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pulmonary Embolism Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pulmonary Embolism Drug Revenue by Type
4.2.1 Global Pulmonary Embolism Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Pulmonary Embolism Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Type (2018-2034)
4.3 Global Pulmonary Embolism Drug Price by Type
4.3.1 Global Pulmonary Embolism Drug Price by Type (2018-2024)
4.3.2 Global Pulmonary Embolism Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pulmonary Embolism Drug Sales Quantity by Application
5.1.1 Global Pulmonary Embolism Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Pulmonary Embolism Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pulmonary Embolism Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pulmonary Embolism Drug Revenue by Application
5.2.1 Global Pulmonary Embolism Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Pulmonary Embolism Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Application (2018-2034)
5.3 Global Pulmonary Embolism Drug Price by Application
5.3.1 Global Pulmonary Embolism Drug Price by Application (2018-2024)
5.3.2 Global Pulmonary Embolism Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pulmonary Embolism Drug Sales by Company
6.1.1 North America Pulmonary Embolism Drug Revenue by Company (2018-2024)
6.1.2 North America Pulmonary Embolism Drug Sales Quantity by Company (2018-2024)
6.2 North America Pulmonary Embolism Drug Market Size by Type
6.2.1 North America Pulmonary Embolism Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Pulmonary Embolism Drug Revenue by Type (2018-2034)
6.3 North America Pulmonary Embolism Drug Market Size by Application
6.3.1 North America Pulmonary Embolism Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Pulmonary Embolism Drug Revenue by Application (2018-2034)
6.4 North America Pulmonary Embolism Drug Market Size by Country
6.4.1 North America Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Pulmonary Embolism Drug Revenue by Country (2018-2034)
6.4.3 North America Pulmonary Embolism Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pulmonary Embolism Drug Sales by Company
7.1.1 Europe Pulmonary Embolism Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Pulmonary Embolism Drug Revenue by Company (2018-2024)
7.2 Europe Pulmonary Embolism Drug Market Size by Type
7.2.1 Europe Pulmonary Embolism Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Pulmonary Embolism Drug Revenue by Type (2018-2034)
7.3 Europe Pulmonary Embolism Drug Market Size by Application
7.3.1 Europe Pulmonary Embolism Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Pulmonary Embolism Drug Revenue by Application (2018-2034)
7.4 Europe Pulmonary Embolism Drug Market Size by Country
7.4.1 Europe Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Pulmonary Embolism Drug Revenue by Country (2018-2034)
7.4.3 Europe Pulmonary Embolism Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pulmonary Embolism Drug Sales by Company
8.1.1 China Pulmonary Embolism Drug Sales Quantity by Company (2018-2024)
8.1.2 China Pulmonary Embolism Drug Revenue by Company (2018-2024)
8.2 China Pulmonary Embolism Drug Market Size by Type
8.2.1 China Pulmonary Embolism Drug Sales Quantity by Type (2018-2034)
8.2.2 China Pulmonary Embolism Drug Revenue by Type (2018-2034)
8.3 China Pulmonary Embolism Drug Market Size by Application
8.3.1 China Pulmonary Embolism Drug Sales Quantity by Application (2018-2034)
8.3.2 China Pulmonary Embolism Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pulmonary Embolism Drug Sales by Company
9.1.1 APAC Pulmonary Embolism Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Pulmonary Embolism Drug Revenue by Company (2018-2024)
9.2 APAC Pulmonary Embolism Drug Market Size by Type
9.2.1 APAC Pulmonary Embolism Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Pulmonary Embolism Drug Revenue by Type (2018-2034)
9.3 APAC Pulmonary Embolism Drug Market Size by Application
9.3.1 APAC Pulmonary Embolism Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Pulmonary Embolism Drug Revenue by Application (2018-2034)
9.4 APAC Pulmonary Embolism Drug Market Size by Region
9.4.1 APAC Pulmonary Embolism Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Pulmonary Embolism Drug Revenue by Region (2018-2034)
9.4.3 APAC Pulmonary Embolism Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pulmonary Embolism Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Pulmonary Embolism Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pulmonary Embolism Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pulmonary Embolism Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Accu-Break Pharmaceuticals, Inc.
11.1.1 Accu-Break Pharmaceuticals, Inc. Company Information
11.1.2 Accu-Break Pharmaceuticals, Inc. Overview
11.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Products and Services
11.1.5 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug SWOT Analysis
11.1.6 Accu-Break Pharmaceuticals, Inc. Recent Developments
11.2 Dong-A Socio Holdings Co. Ltd.
11.2.1 Dong-A Socio Holdings Co. Ltd. Company Information
11.2.2 Dong-A Socio Holdings Co. Ltd. Overview
11.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Products and Services
11.2.5 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug SWOT Analysis
11.2.6 Dong-A Socio Holdings Co. Ltd. Recent Developments
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Company Information
11.3.2 F. Hoffmann-La Roche Ltd. Overview
11.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Products and Services
11.3.5 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug SWOT Analysis
11.3.6 F. Hoffmann-La Roche Ltd. Recent Developments
11.4 Genentech, Inc.
11.4.1 Genentech, Inc. Company Information
11.4.2 Genentech, Inc. Overview
11.4.3 Genentech, Inc. Pulmonary Embolism Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Genentech, Inc. Pulmonary Embolism Drug Products and Services
11.4.5 Genentech, Inc. Pulmonary Embolism Drug SWOT Analysis
11.4.6 Genentech, Inc. Recent Developments
11.5 Verseon Corp
11.5.1 Verseon Corp Company Information
11.5.2 Verseon Corp Overview
11.5.3 Verseon Corp Pulmonary Embolism Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Verseon Corp Pulmonary Embolism Drug Products and Services
11.5.5 Verseon Corp Pulmonary Embolism Drug SWOT Analysis
11.5.6 Verseon Corp Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pulmonary Embolism Drug Value Chain Analysis
12.2 Pulmonary Embolism Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pulmonary Embolism Drug Production Mode & Process
12.4 Pulmonary Embolism Drug Sales and Marketing
12.4.1 Pulmonary Embolism Drug Sales Channels
12.4.2 Pulmonary Embolism Drug Distributors
12.5 Pulmonary Embolism Drug Customers
13 Market Dynamics
13.1 Pulmonary Embolism Drug Industry Trends
13.2 Pulmonary Embolism Drug Market Drivers
13.3 Pulmonary Embolism Drug Market Challenges
13.4 Pulmonary Embolism Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of DS-9231
Table 3. Major Manufacturers of DS-1040
Table 4. Major Manufacturers of TRX-1
Table 5. Major Manufacturers of Others
Table 6. Global Pulmonary Embolism Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Pulmonary Embolism Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Pulmonary Embolism Drug Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Pulmonary Embolism Drug Revenue Market Share by Region (2018-2024)
Table 10. Global Pulmonary Embolism Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Pulmonary Embolism Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Pulmonary Embolism Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 13. Global Pulmonary Embolism Drug Sales by Region (2018-2024) & (K Pcs)
Table 14. Global Pulmonary Embolism Drug Sales Market Share by Region (2018-2024)
Table 15. Global Pulmonary Embolism Drug Sales by Region (2024-2034) & (K Pcs)
Table 16. Global Pulmonary Embolism Drug Sales Market Share by Region (2024-2034)
Table 17. Global Pulmonary Embolism Drug Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 18. Global Pulmonary Embolism Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Pulmonary Embolism Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Pulmonary Embolism Drug Revenue Share by Manufacturers (2018-2024)
Table 21. Global Pulmonary Embolism Drug Price by Manufacturers 2018-2024 (USD/Pcs)
Table 22. Global Key Players of Pulmonary Embolism Drug, Industry Ranking, 2021 VS 2022
Table 23. Global Pulmonary Embolism Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Pulmonary Embolism Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Embolism Drug as of 2022)
Table 25. Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Pulmonary Embolism Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Pulmonary Embolism Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Pulmonary Embolism Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 30. Global Pulmonary Embolism Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 31. Global Pulmonary Embolism Drug Sales Quantity Share by Type (2018-2024)
Table 32. Global Pulmonary Embolism Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Pulmonary Embolism Drug Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Pulmonary Embolism Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Pulmonary Embolism Drug Revenue Share by Type (2018-2024)
Table 36. Global Pulmonary Embolism Drug Revenue Share by Type (2024-2034)
Table 37. Pulmonary Embolism Drug Price by Type (2018-2024) & (USD/Pcs)
Table 38. Global Pulmonary Embolism Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 39. Global Pulmonary Embolism Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 40. Global Pulmonary Embolism Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 41. Global Pulmonary Embolism Drug Sales Quantity Share by Application (2018-2024)
Table 42. Global Pulmonary Embolism Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Pulmonary Embolism Drug Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Pulmonary Embolism Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Pulmonary Embolism Drug Revenue Share by Application (2018-2024)
Table 46. Global Pulmonary Embolism Drug Revenue Share by Application (2024-2034)
Table 47. Pulmonary Embolism Drug Price by Application (2018-2024) & (USD/Pcs)
Table 48. Global Pulmonary Embolism Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 49. North America Pulmonary Embolism Drug Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Pulmonary Embolism Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 51. North America Pulmonary Embolism Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 52. North America Pulmonary Embolism Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 53. North America Pulmonary Embolism Drug Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Pulmonary Embolism Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Pulmonary Embolism Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 56. North America Pulmonary Embolism Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 57. North America Pulmonary Embolism Drug Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Pulmonary Embolism Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Pulmonary Embolism Drug Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Pulmonary Embolism Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Pulmonary Embolism Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 63. North America Pulmonary Embolism Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 64. Europe Pulmonary Embolism Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 65. Europe Pulmonary Embolism Drug Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Pulmonary Embolism Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 67. Europe Pulmonary Embolism Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 68. Europe Pulmonary Embolism Drug Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Pulmonary Embolism Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Pulmonary Embolism Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 71. Europe Pulmonary Embolism Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 72. Europe Pulmonary Embolism Drug Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Pulmonary Embolism Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Pulmonary Embolism Drug Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Pulmonary Embolism Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Pulmonary Embolism Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 78. Europe Pulmonary Embolism Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 79. China Pulmonary Embolism Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 80. China Pulmonary Embolism Drug Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Pulmonary Embolism Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 82. China Pulmonary Embolism Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 83. China Pulmonary Embolism Drug Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Pulmonary Embolism Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Pulmonary Embolism Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 86. China Pulmonary Embolism Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 87. China Pulmonary Embolism Drug Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Pulmonary Embolism Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Pulmonary Embolism Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 90. APAC Pulmonary Embolism Drug Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Pulmonary Embolism Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 92. APAC Pulmonary Embolism Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 93. APAC Pulmonary Embolism Drug Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Pulmonary Embolism Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Pulmonary Embolism Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 96. APAC Pulmonary Embolism Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 97. APAC Pulmonary Embolism Drug Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Pulmonary Embolism Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Pulmonary Embolism Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Pulmonary Embolism Drug Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Pulmonary Embolism Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Pulmonary Embolism Drug Sales Quantity by Region (2018-2024) & (K Pcs)
Table 103. APAC Pulmonary Embolism Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 104. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Company (2018-2024) & (K Pcs)
Table 105. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Type (2018-2024) & (K Pcs)
Table 107. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 108. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Application (2018-2024) & (K Pcs)
Table 111. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 112. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Country (2018-2024) & (K Pcs)
Table 118. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 119. Accu-Break Pharmaceuticals, Inc. Company Information
Table 120. Accu-Break Pharmaceuticals, Inc. Description and Overview
Table 121. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 122. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product and Services
Table 123. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug SWOT Analysis
Table 124. Accu-Break Pharmaceuticals, Inc. Recent Developments
Table 125. Dong-A Socio Holdings Co. Ltd. Company Information
Table 126. Dong-A Socio Holdings Co. Ltd. Description and Overview
Table 127. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product and Services
Table 129. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug SWOT Analysis
Table 130. Dong-A Socio Holdings Co. Ltd. Recent Developments
Table 131. F. Hoffmann-La Roche Ltd. Company Information
Table 132. F. Hoffmann-La Roche Ltd. Description and Overview
Table 133. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 134. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product and Services
Table 135. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug SWOT Analysis
Table 136. F. Hoffmann-La Roche Ltd. Recent Developments
Table 137. Genentech, Inc. Company Information
Table 138. Genentech, Inc. Description and Overview
Table 139. Genentech, Inc. Pulmonary Embolism Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 140. Genentech, Inc. Pulmonary Embolism Drug Product and Services
Table 141. Genentech, Inc. Pulmonary Embolism Drug SWOT Analysis
Table 142. Genentech, Inc. Recent Developments
Table 143. Verseon Corp Company Information
Table 144. Verseon Corp Description and Overview
Table 145. Verseon Corp Pulmonary Embolism Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 146. Verseon Corp Pulmonary Embolism Drug Product and Services
Table 147. Verseon Corp Pulmonary Embolism Drug SWOT Analysis
Table 148. Verseon Corp Recent Developments
Table 149. Key Raw Materials Lists
Table 150. Raw Materials Key Suppliers Lists
Table 151. Pulmonary Embolism Drug Distributors List
Table 152. Pulmonary Embolism Drug Customers List
Table 153. Pulmonary Embolism Drug Market Trends
Table 154. Pulmonary Embolism Drug Market Drivers
Table 155. Pulmonary Embolism Drug Market Challenges
Table 156. Pulmonary Embolism Drug Market Restraints
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Embolism Drug Product Picture
Figure 2. Global Pulmonary Embolism Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pulmonary Embolism Drug Market Share by Type in 2022 & 2034
Figure 4. DS-9231 Product Picture
Figure 5. DS-1040 Product Picture
Figure 6. TRX-1 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Pulmonary Embolism Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Pulmonary Embolism Drug Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Pulmonary Embolism Drug Report Years Considered
Figure 14. Global Pulmonary Embolism Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Pulmonary Embolism Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Pulmonary Embolism Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Pulmonary Embolism Drug Sales Quantity 2018-2034 (K Pcs)
Figure 18. Global Pulmonary Embolism Drug Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Pulmonary Embolism Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Pulmonary Embolism Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. North America Pulmonary Embolism Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Pulmonary Embolism Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. Europe Pulmonary Embolism Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Pulmonary Embolism Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. China Pulmonary Embolism Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Pulmonary Embolism Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. APAC Pulmonary Embolism Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Pulmonary Embolism Drug Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Pulmonary Embolism Drug Revenue in 2022
Figure 32. Pulmonary Embolism Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Pulmonary Embolism Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Pulmonary Embolism Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Pulmonary Embolism Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Pulmonary Embolism Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Pulmonary Embolism Drug Revenue Market Share by Company in 2022
Figure 38. North America Pulmonary Embolism Drug Sales Quantity Market Share by Company in 2022
Figure 39. North America Pulmonary Embolism Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Pulmonary Embolism Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Pulmonary Embolism Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Pulmonary Embolism Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Pulmonary Embolism Drug Revenue Share by Country (2018-2034)
Figure 44. North America Pulmonary Embolism Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Pulmonary Embolism Drug Sales Quantity Market Share by Company in 2022
Figure 48. Europe Pulmonary Embolism Drug Revenue Market Share by Company in 2022
Figure 49. Europe Pulmonary Embolism Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Pulmonary Embolism Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Pulmonary Embolism Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Pulmonary Embolism Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Pulmonary Embolism Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Pulmonary Embolism Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Pulmonary Embolism Drug Sales Quantity Market Share by Company in 2022
Figure 61. China Pulmonary Embolism Drug Revenue Market Share by Company in 2022
Figure 62. China Pulmonary Embolism Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Pulmonary Embolism Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Pulmonary Embolism Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Pulmonary Embolism Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Pulmonary Embolism Drug Sales Quantity Market Share by Company in 2022
Figure 67. APAC Pulmonary Embolism Drug Revenue Market Share by Company in 2022
Figure 68. APAC Pulmonary Embolism Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Pulmonary Embolism Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Pulmonary Embolism Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Pulmonary Embolism Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Pulmonary Embolism Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Pulmonary Embolism Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Pulmonary Embolism Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Pulmonary Embolism Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Pulmonary Embolism Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Pulmonary Embolism Drug Value Chain
Figure 93. Pulmonary Embolism Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed